{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T04:47:29Z","timestamp":1772945249448,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","award":["785\/22"],"award-info":[{"award-number":["785\/22"]}],"id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004375","name":"Tel Aviv University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004375","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["758313"],"award-info":[{"award-number":["758313"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007028","name":"Leona M and Harry B Helmsley Charitable Trust","doi-asserted-by":"publisher","award":["1165359"],"award-info":[{"award-number":["1165359"]}],"id":[{"id":"10.13039\/100007028","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.dld.2025.08.071","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T03:17:53Z","timestamp":1757301473000},"page":"2128-2134","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Overcoming anti-Infliximab antibodies and maintaining Infliximab achieves superior durability and outcome compared to switching to Adalimumab"],"prefix":"10.1016","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1553-5847","authenticated-orcid":false,"given":"Maya","family":"Granot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nurit","family":"Nachum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Krauthammer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tal David","family":"Berger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophia","family":"Heiman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miri","family":"Yavzori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orit","family":"Picard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shomron","family":"Ben-Horin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Batia","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yael","family":"Haberman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2025.08.071_bib0001","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2025.08.071_bib0002","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/ibd.21349","article-title":"Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends","volume":"17","author":"Benchimol","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2025.08.071_bib0003","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-025-08940-0","article-title":"Global evolution of inflammatory bowel disease across epidemiologic stages","author":"Hracs","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.dld.2025.08.071_bib0004","doi-asserted-by":"crossref","DOI":"10.1111\/apt.18264","article-title":"Differences in disease characteristics and treatment exposures between paediatric and adult-onset inflammatory bowel disease using a registry-based cohort","author":"Granot","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2025.08.071_bib0005","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrgastro.2009.124","article-title":"Mechanisms of growth impairment in pediatric Crohn's disease","volume":"6","author":"Walters","year":"2009","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2025.08.071_bib0006","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1111\/apt.18310","article-title":"Editorial: distinct challenges of paediatric from adult-onset inflammatory bowel disease, implications of aggressive disease phenotypes and early biologic therapy in children-authors' Reply","volume":"60","author":"Granot","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2025.08.071_bib0007","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","article-title":"Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children","volume":"132","author":"Hyams","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2025.08.071_bib0008","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.cgh.2011.11.026","article-title":"Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis","volume":"10","author":"Hyams","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2025.08.071_bib0009","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1093\/ecco-jcc\/jjv096","article-title":"Infliximab-related infusion reactions: systematic review","volume":"9","author":"Lichtenstein","year":"2015","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2025.08.071_bib0010","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.cgh.2014.07.029","article-title":"Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab","volume":"13","author":"Yanai","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2025.08.071_bib0011","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2025.08.071_bib0012","article-title":"The Medical Management of Paediatric Crohn's Disease: an ECCO-ESPGHAN guideline update","author":"van Rheenen","year":"2020","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2025.08.071_bib0013","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1136\/gutjnl-2013-305259","article-title":"The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab","volume":"63","author":"Ungar","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.dld.2025.08.071_bib0014","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2468-1253(19)30012-3","article-title":"Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study","volume":"4","author":"Kennedy","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2025.08.071_bib0015","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/ibd\/izy010","article-title":"The impact of combination therapy on infliximab levels and antibodies in children and young adults with inflammatory bowel disease","volume":"24","author":"Chi","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2025.08.071_bib0016","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/MPG.0000000000001551","article-title":"Less anti-infliximab antibody formation in paediatric crohn patients on concomitant immunomodulators","volume":"65","author":"Kansen","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.dld.2025.08.071_bib0017","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1053\/j.gastro.2019.09.041","article-title":"HLA-DQA1\u00d705 carriage associated with development of anti-drug antibodies to Infliximab and Adalimumab in patients with Crohn's Disease","volume":"158","author":"Sazonovs","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2025.08.071_bib0018","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/joim.13495","article-title":"Risk factors for anti-drug antibody formation to infliximab: secondary analyses of a randomised controlled trial","volume":"292","author":"Brun","year":"2022","journal-title":"J Intern Med"},{"key":"10.1016\/j.dld.2025.08.071_bib0019","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/jpn3.12041","article-title":"Effectiveness of strategies to suppress antibodies to infliximab in pediatric inflammatory bowel disease","volume":"78","author":"Jagt","year":"2024","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.dld.2025.08.071_bib0020","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/MPG.0000000000001029","article-title":"Practical use of Infliximab concentration monitoring in pediatric Crohn disease","volume":"62","author":"Minar","year":"2016","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.dld.2025.08.071_bib0021","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/ibd\/izaa108","article-title":"Favorable outcomes and anti-TNF durability after addition of an immunomodulator for anti-drug antibodies in pediatric IBD patients","volume":"27","author":"Colman","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2025.08.071_bib0022","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/apt.16733","article-title":"Antibodies-to-infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn's disease","volume":"55","author":"Colman","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2025.08.071_bib0023","doi-asserted-by":"crossref","first-page":"329","DOI":"10.5223\/pghn.2018.21.4.329","article-title":"Reversal of immunogenicity in pediatric inflammatory bowel disease patients receiving anti-tumor necrosis factor medications","volume":"21","author":"Kang","year":"2018","journal-title":"Pediatr Gastroenterol Hepatol Nutr"},{"key":"10.1016\/j.dld.2025.08.071_bib0024","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1093\/ecco-jcc\/jjab204","article-title":"Improved outcomes of paediatric and adult Crohn's disease and association with emerging use of biologics-A nationwide study from the Epi-IIRN","volume":"16","author":"Atia","year":"2022","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2025.08.071_bib0025","article-title":"Durability of Adalimumab and Infliximab in children with Crohn's Disease: a nationwide comparison from the epi-IIRN cohort","author":"Atia","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2025.08.071_bib0026","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1111\/apt.17170","article-title":"Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second anti-TNF therapy (IMSAT) therapeutic drug monitoring study","volume":"56","author":"Chanchlani","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2025.08.071_bib0027","doi-asserted-by":"crossref","DOI":"10.1177\/17562848231222337","article-title":"Early infliximab trough levels in paediatric IBD patients predict sustained remission","volume":"17","author":"Bevers","year":"2024","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.dld.2025.08.071_bib0028","first-page":"63","article-title":"Comparison of timing to develop anti-drug antibodies to Infliximab and Adalimumab between adult and pediatric age groups, males and females","volume":"27","author":"Trotta","year":"2022","journal-title":"J Pediatr Pharmacol Ther"},{"key":"10.1016\/j.dld.2025.08.071_bib0029","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1093\/ibd\/izad277","article-title":"Pediatric IBD patients treated with Infliximab and proactive drug monitoring benefit from early concomitant immunomodulatory therapy: a retrospective analysis of a 10-year real-life cohort","volume":"30","author":"Hoelz","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2025.08.071_bib0030","first-page":"1","article-title":"The efficacy of immunomodulators in the prevention and suppression of anti-drug antibodies to anti-tumor necrosis factor therapy in inflammatory bowel disease","volume":"35","author":"Fousekis","year":"2022","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.dld.2025.08.071_bib0031","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1007\/s10620-021-07088-x","article-title":"High anti-infliximab antibody titers do not impact response to subsequent adalimumab treatment in inflammatory bowel diseases","volume":"67","author":"Sasson","year":"2022","journal-title":"Dig Dis Sci"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865825010515?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865825010515?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T14:01:54Z","timestamp":1772892114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865825010515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1590865825010515"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2025.08.071","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overcoming anti-Infliximab antibodies and maintaining Infliximab achieves superior durability and outcome compared to switching to Adalimumab","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2025.08.071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}